Session » (1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1556

Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome

9:00AM-11:00AM: Abstract Number: 1577

Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome

9:00AM-11:00AM: Abstract Number: 1576

Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria

9:00AM-11:00AM: Abstract Number: 1567

Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 1555

Axial Spondyloarthritis in Patients with Gastrointestinal Involvement of Behçet Syndrome

9:00AM-11:00AM: Abstract Number: 1565

Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months

9:00AM-11:00AM: Abstract Number: 1562

Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population

9:00AM-11:00AM: Abstract Number: 1561

Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study

9:00AM-11:00AM: Abstract Number: 1564

Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1568

Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 1559

Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease

9:00AM-11:00AM: Abstract Number: 1557

De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome

9:00AM-11:00AM: Abstract Number: 1560

Decreased Level of Peripheral CLA+ Treg Is a Protective Factor of Nervous System Involvement in Behcet’s Syndrome: A Real-World Study in China

9:00AM-11:00AM: Abstract Number: 1558

Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

9:00AM-11:00AM: Abstract Number: 1569

Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study

9:00AM-11:00AM: Abstract Number: 1566

Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1578

Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 1573

Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020

9:00AM-11:00AM: Abstract Number: 1572

Long-term Efficacy and Retention Rate of Molecular Targeted Drugs in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 1563

Methotrexate: A Safe and Effective Therapeutic Alternative in Behçet´s Disease

9:00AM-11:00AM: Abstract Number: 1570

Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study

9:00AM-11:00AM: Abstract Number: 1575

Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study

9:00AM-11:00AM: Abstract Number: 1574

The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 1554

Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study

9:00AM-11:00AM: Abstract Number: 1571

Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].